Portfolio

High-impact
therapeutics

Through a disciplined approach to diligence and acquisition, CinRx Pharma has assembled a robust portfolio of therapeutics spanning multiple disease areas. We focus on identifying assets where unmet patient need is significant and outcomes can be meaningfully improved.

Active CinCos

Programs advancing today

Each CinCo is focused on a single high-priority therapeutic asset and supported by the CinRx central execution team.

Active program

CinPressa Pharma

Cardiometabolic

Rapidly advancing a high-potential therapeutic asset toward the clinic.

CinPressa Pharma is advancing a differentiated, high-potential therapeutic asset toward first-in-human studies, leveraging CinRx's centralized clinical and regulatory infrastructure.

Visit CinPressa Pharma

Active program

CinDome Pharma

Gastroenterology

Restoring quality of life for patients with gastroparesis.

CinDome Pharma is advancing deudomperidone (CIN-102) as a safe, chronic therapy for patients with gastroparesis, a chronic and underserved condition.

AssetDeudomperidone (CIN-102)

Visit CinDome Pharma

Validation Through Exit

The CinRx model, validated

A successful exit is the clearest evidence of the model, and a marker of more to come.

Validation exit

CinCor Pharma

Cardiometabolic

Acquired by AstraZeneca.

A landmark validation of the CinRx operating model. CinCor's lead cardiometabolic asset was successfully advanced and the company acquired by AstraZeneca.

Acquired byAstraZeneca

Visit the product site

Asset diligence

Have an asset that could be the next CinCo?

We're actively evaluating high-potential therapeutic assets across multiple disease areas. If you think your program fits our model, we'd like to hear from you.

Start a conversation Partnering inquiries